IN8bio (INAB) Stock Price, News & Analysis

Company Overview

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Key Stats

• Today's Range: $0.33 to $0.37
• 50-Day Range: $0.23 to $0.50
• 52-Week Range: $0.22 to $2.48
• Volume: 441,787 shs
• Average Volume: 547,612 shs
• Market Capitalization: $16.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

IN8bio Stock Analysis - MarketRank™

IN8bio scored higher than 68% of companies evaluated by MarketBeat, and ranked 246th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IN8bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IN8bio are expected to grow in the coming year, from ($0.52) to ($0.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IN8bio is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IN8bio is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IN8bio has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.12% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently increased by 578.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IN8bio does not currently pay a dividend.

Dividend Growth

IN8bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.12% of the float of IN8bio has been sold short.

Short Interest Ratio / Days to Cover

IN8bio has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IN8bio has recently increased by 578.43%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.30

News Sentiment

IN8bio has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for IN8bio this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added IN8bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IN8bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.50% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INAB Stock Analysis - Frequently Asked Questions

How have INAB shares performed this year?

IN8bio's stock was trading at $1.38 at the beginning of the year. Since then, INAB stock has decreased by 74.9% and is now trading at $0.3470.
View the best growth stocks for 2024 here.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03.

When did IN8bio IPO?

IN8bio (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

Who are IN8bio's major shareholders?

Top institutional investors of IN8bio include Sigma Planning Corp (1.82%). Insiders that own company stock include William Tai-Wei Ho, Lawrence Lamb, Patrick Mccall, Kate Rochlin, Trishna Goswami and Jeremy R Graff.
View institutional ownership trends.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of IN8bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IN8bio investors own include NVIDIA (NVDA), Ford Motor (F), GitLab (GTLB), Cognition Therapeutics (CGTX), CrowdStrike (CRWD), Chevron (CVX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/12/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INAB
• CUSIP: N/A
• CIK: 1740279
• Web: www.in8bio.com
• Phone: 646-600-6438
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $12.50
• Low Stock Price Target: $7.50
• Potential Upside/Downside: +2,781.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,010,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -173.12%
• Return on Assets: -118.40%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 46,787,000
• Free Float: 39,535,000
• Market Cap: $16.24 million
• Optionable: Not Optionable
• Beta: -0.07